It is increasingly clear that a tailored therapeutic approach to patients with hepatitis C virus infection is needed. Success rates in difficult to treat and low-responsive hepatitis C virus patients are not completely satisfactory, and there is the need to optimise treatment duration and intensity in patients with the highest likelihood of response. In addition, the management of special patient categories originally excluded from phase III registration trials needs to be critically re-evaluated. This article reports the recommendations for the treatment of hepatitis C virus infection on an individual basis, drafted by experts of three scientific societies.

Practice guidelines for the treatment of hepatitis C : recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting / D. Prati, A. Gasbarrini, F. Mazzotta, E. Sagnelli, G. Carosi, N. Abrescia, A. Alberti, S. Ambu, P. Andreone, A. Andriulli, M. Angelico, G. Antonucci, A. Ascione, L.S. Belli, R. Bruno, S. Bruno, P. Burra, C. Camma, N. Caporaso, G. Cariti, U. Cillo, N. Coppola, A. Craxi, A. De Luca, E. De Martin, V. Di Marco, S. Fagiuoli, C. Ferrari, G.B. Gaeta, M. Galli, A. Grieco, P. Grossi, A. Licata, I. Maida, A. Mangia, N. Marino, R. Maserati, G. Missale, M. Mondelli, P. Nasta, G. Niro, M. Persico, E. Petrelli, A. Picciotto, F. Piscaglia, T. Pollicino, D. Prati, C. Puoti, M. Puoti, G. Raimondo, M.G. Rumi, E. Sagnelli, T. Santantonio, A. Smedile, G. Squadrito, G.S. Baroni, G. Taliani, M. Tavio, M. Toti, F. Bonino, M.R. Brunetto, B. Cacopardo, M. Caremani, R. Cauda, M. Colombo, G. Di Perri, F. Donato, P. Farci, G. Fattovich, G. Filice, F. Ghinelli, V. Guadagnino, A. Lazzarin, M. Levrero, G. Licata, A. Orani, A. Paffetti, G. Pastore, F. Piccinino, E. Pizzigallo, P. Pontisso, V. Portelli, M. Rizzetto, A. Rossi, T. Stroffolini, E. Ubaldi, T. Santantanio, A. Alberti, P. Grossi, G.F. Antonucci. - In: DIGESTIVE AND LIVER DISEASE. - ISSN 1590-8658. - 42:2(2010 Feb), pp. 81-91. [10.1016/j.dld.2009.08.001]

Practice guidelines for the treatment of hepatitis C : recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting

M. Galli;M.G. Rumi;
2010

Abstract

It is increasingly clear that a tailored therapeutic approach to patients with hepatitis C virus infection is needed. Success rates in difficult to treat and low-responsive hepatitis C virus patients are not completely satisfactory, and there is the need to optimise treatment duration and intensity in patients with the highest likelihood of response. In addition, the management of special patient categories originally excluded from phase III registration trials needs to be critically re-evaluated. This article reports the recommendations for the treatment of hepatitis C virus infection on an individual basis, drafted by experts of three scientific societies.
Interferon-alpha; Hepacivirus; Recombinant Proteins; Humans; Ribavirin; Liver Cirrhosis; Antiviral Agents; Drug Therapy, Combination; Genotype; Drug Resistance, Viral; HIV Infections; Hepatitis B, Chronic; Hepatitis C; Polyethylene Glycols; Hepatitis C, Chronic
Settore MED/17 - Malattie Infettive
feb-2010
Article (author)
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/355977
Citazioni
  • ???jsp.display-item.citation.pmc??? 18
  • Scopus 60
  • ???jsp.display-item.citation.isi??? 54
social impact